New Drug Identified May Help Effectively Treat COVID-19 Pneumonia: Lancet Study
NDTV
COVID-19 Research: The team, including researchers from the University of Birmingham and the University of Oxford, UK, tested namilumab - an antibody already in late-stage trials to treat rheumatoid arthritis - in patients hospitalised with COVID-19 pneumonia.
A newly identified drug may be used to effectively treat some patients hospitalised with COVID-19 pneumonia, according to a study published in The Lancet Respiratory Medicine journal.
The team, including researchers from the University of Birmingham and the University of Oxford, UK, tested namilumab - an antibody already in late-stage trials to treat rheumatoid arthritis - in patients hospitalised with COVID-19 pneumonia.
The patients were receiving 'usual' care, as well as having high levels in their blood of a marker of inflammation known as C reactive protein (CRP).
CRP levels rise when there is inflammation in the body, and elevated levels of CRP have been found to be a potential early marker to predict risk for severity of COVID-19, the researchers said.
